A California-based company is seeking US Food and Drug Administration (FDA) authorisation to market what it calls the first “vapour-style inhalable” nicotine replacement therapy (NRT) device
Submit your access request to explore how it streamlines access to critical market and regulatory insights
"*" indicates required fields